Navigation Links
Better treatment selection and improved therapies -- key to improving prognosis in acute HF
Date:5/30/2009

Today, acute heart failure represents the most common reason for hospitalisation in the over-65 population. Although hospital care improves symptoms in the first 24 hours after admission in around 50% of these patients, acute heart failure events still remain associated with a more than 50% mortality and rehospitalisation rate at 6-12 months. "Indeed," says Professor Marco Metra from the Cardiology Department of the University of Brescia, Italy, "it is the very rapid onset of symptoms and the need for urgent therapy which characterise the condition."1,2

Treatments in acute heart failure, he adds, have not undergone any great change in recent decades, despite the demand of heart failure's increasing prevalence and huge personal and public impact. Professor Metra said that treatments are still based on loop diuretics (furosemide), peripheral vasodilators (nitrates) and inotropic agents. Even the more recently approved treatments, he added, such as levosimendan in Europe and nesiritide in the USA, have been associated with uncertain effects on outcomes in randomised trials. "So hospitalisations for acute heart failure are still associated with high mortality and rehospitalisation rates," he says. "The burden is tremendous because of the large number of patients involved, their poor prognosis and the costs of the treatment."

In a presentation at Heart Failure Congress 2009 Professor Metra defined two major pathways along which this burden might be reduced and treatment improved:

* Better selection of treatments. To date, he said, therapy in acute heart failure has been administered with little attention to the clinical presentation of each patient. Guidelines on heart failure issued by the European Society of Cardiology in 2008 define heart failure as a heterogeneous condition and recommend that different therapies are used on the basis of clinical presentation; for example, patients with fluid overload should undergo fluid removal through diuretics or other means, patients with high blood pressure should receive mainly vasodilators, and patients with low cardiac output should be treated with inotropic agents to improve the force of the heart muscle's contraction.3

* Improved therapies. Many new agents are currently under development, said Professor Metra, which include adenosine type 1 receptors antagonists to enhance the diuretic effects of furosemide and increase renal blood flow, new vasodilators with different mechanisms of action, and new inotropic agents.

"Better treatment selection and the development of new agents give us some hope that we will finally be able to improve the symptoms and prognosis of such a large patient population as that suffering from acute heart failure," says Professor Metra. However, he also emphasised that urgent therapy is one of the key recommendations of the latest European guidelines.


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-062-241-8492
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
3. Informational handout key to giving parents a better understanding of CT radiation risks
4. Children of depressed moms do better when dad is involved, SLU researcher finds
5. Struggling male readers respond better to female teachers
6. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
7. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
8. Researchers Find Better Way to Deliver Blood Thinner
9. Clinical trials present better alternatives for dialysis patients
10. New nurses report job stress, need for better management
11. Hispanics hypertension better controlled with equal access to care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 20, 2017 , ... “The Angel”: a heartwarming and earnest tale of ... of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a ... and impassioned writer. , When asked of her new book, Marjorie says, “‘The Angel’ ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare ... device, was featured in a study indicating superior performance against competitive products in ... of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Knowledge is ... be guided by faith. “Knowledge is God’s Lighthouse” is the creation of published author, ... cookbooks, novels, and poetry collections. , “I have been writing since high school ...
(Date:1/19/2017)... ... January 20, 2017 , ... Today, the Centers for ... in four of CMS’s Alternative Payment Models (APMs) in 2017. Clinicians who participate in ... APMs are an important part of the Administration’s effort to build a system that ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells ... facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. , ... physicians and patients throughout the United States for high-quality human anti-aging and ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... January 19, 2017 ... Oncology & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to ... from touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
Breaking Medicine Technology: